You are in:Home/Publications/Safety and efficacy of Ivabradine in patients with acute ST-segment elevation myocardial infarction (STEMI)

Prof. Mohamed Abdou Mohamed Salem :: Publications:

Title:
Safety and efficacy of Ivabradine in patients with acute ST-segment elevation myocardial infarction (STEMI)
Authors: Mohamed Salem1, Mohamed El Sayed2, Mohamed Abdel Kader1, Ahmed Abdel Moniem1
Year: 2015
Keywords: Not Available
Journal: International Journal of Cardiology and Cardiovascular Research
Volume: 2
Issue: 1
Pages: Not Available
Publisher: Not Available
Local/International: International
Paper Link: Not Available
Full paper Mohamed Abdou Mohamed Salem_Paper 4.pdf
Supplementary materials Not Available
Abstract:

ST segment elevation myocardial infarction (STEMI) is commonly induced by thrombus formation leading to complete occlusion of a major epicardial coronary vessel. We aimed to explore safety and efficacy of Ivabradine in patients with STEMI associated with left ventricular dysfunction. 200 consecutive patients with STEMI were included in this controlled study. All patients had successful reperfusion and LVEF less than 50%. 100 patients received 5 mg ivabradine twice a day in addition to the conventional treatment, while 100 patients received the conventional treatment only. Composite end point of death, re-infarction, overt heart failure, or need for revascularization was reported at 30 days. Ivabradine when added to the conventional treatment reduced the heart rate significantly compared to the conventional treatment alone. However it did not affect incidence of primary end point. Ivabradine didn't show a significant impact on major adverse cardiac events when added to conventional treatment.

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus